Natriuretic peptides and panic disorder: Therapeutic prospects

Expert Review of Neurotherapeutics

Volumn 3, Issue 3, 2003, Pages 381-386

  Kellner, Michael ^a   Jahn, Holger ^a   Wiedemann, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Anxiety; Atrial natriuretic peptide; C type natriuretic peptide; HPA axis; Panic

Indexed keywords

ATRIAL NATRIURETIC FACTOR DERIVATIVE; CORTICOTROPIN RELEASING FACTOR; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; NATRIURETIC PEPTIDE TYPE C ANTAGONIST; TETRAGASTRIN; UNCLASSIFIED DRUG;

ANXIETY; CENTRAL NERVOUS SYSTEM; DISEASE ASSOCIATION; DRUG ACTIVITY; ENDOCRINE FUNCTION; HORMONE RELEASE; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; PANIC; PSYCHOPHARMACOTHERAPY; REVIEW; STRESS;

EID: 0038814238     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.3.3.381     Document Type: Review

References (71)

1. Samson WK Natriuretic peptides. A family of hormones. Trends Endocrinol. Metab. 3, 86-90 (1992).
2. Imura H, Nakao K, Itoh H. The natriuretic peptide system in the brain: implications in the central control of cardiovascular and neuroendocrine functions. Front. Neuroendocrinol. 13, 217-249 (1992). Excellent structured review that is still of considerable interest today.
3. Kaneko T, Shirakami G, Nakao K et al. C-type natriuretic peptide (CNP) is the major natriuretic peptide in human cerebrospinal fluid. Brain Res. 612, 104-109 (1993).
4. Lowe DG, Klisak I, Sparkes RS, Mohandas T, Goeddel DV. Chromosomal distribution of the human natriuretic peptide receptor/guanylyl cyclase gene family. Genomics 8, 304-312 (1990).
5. Wilcox JN, Augustine A, Goeddel DV, Lowe DG. Differential regional expression of three natriuretic peptide receptor genes within primate tissues. Mol. Cell. Biol. 11, 3454-3462 (1991).
6. Herman JP, Dolgas CM, Marcinek R, Langub MC Jr. Expression and glucocorticoid regulation of natriuretic peptide clearance receptor (NPR-C) mRNA in rat brain and choroid plexus. J. Chem Neuroanat. 11, 257-265 (1996).
7. Kukkonen P, Vuolteenaho O, Ruskoaho H. Basal and volume expansion-stimulated plasma atrial natriuretic peptide concentrations and hemodynamics in conscious rats: effects of SCH39.370, an endopeptidase inhibitor and C-ANF-(4-23), a clearance receptor ligand. Endocrinology 130, 755-765 (1992).
8. Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espkner EA, Livesey JH. Metabolic clearance rate and plasma life of α-human atrial natriuretic peptide in man. Life Sci. 38, 1827-1833 (1986).
9. Hunt PJ, Richards AM, Espiner EA, Nicholls MG, Yandle TG. Bioactivity and metabolism of C-type natriuretic peptide in normal man. J. Clin. Endocrinol. Metab. 78, 1428-1435 (1994).
10. Koller KH, Lowe DG, Bennett GL et al. Selective activation of the B natriuretic peptide receptor by the C-type natriuretic peptide (CNP). Science 252, 120-123 (1991).
11. Lopez MJ, Garbers DL, Kuhn M. The guanyl cyclase-deficient mouse defines differential pathways of natriuretic peptide signaling. J. Biol. Chem. 272, 23064-23068 (1997).
12. Langub MC, Watson RE, Herman JP. Distribution of natriuretic peptide precursor mRNAs in the rat brain. J. Comp. Neurology 356, 183-199 (1995b).
13. Langub MC, Dolgas CM, Watson RE, Herman JP. The C-type natriuretic peptide receptor is the predominant natriuretic peptide receptor mRNA expressed in rat hypothalamus. J. Neuroendocrinol. 7, 305-309 (1995a).
14. Sumners C, Tang W. Atrial natriuretic peptide receptor subtypes in rat neuronal and astrocyte glial cultures. Am. J. Physiol. 262, C1134-C1143 (1992).
15. Kurihara M, Saavedra JM, Shigematsu K. Localization and characterization of atrial natriuretic peptide binding sites in discrete areas of rat brain and pituitary gland by quantitative autoradiography. Brain Res. 408, 31-39 (1987).
16. Yeung VTF, Lai CK, Cockram CS et al. Atrial natriuretic peptide in the central nervous system. Neuroendocrinology 53, 18-24 (1991).
17. Holsboer F. The rationale for corticotrophin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J. Psychiatry Res. 33, 181-214 (1999).
18. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. 160, 1-12 (1999).
19. Liebsch GR, Landgraf R, Gerstberger R et al. Chronic infusion of a CRH-1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behaviour in socially defeated rats. Reg. Peptides 59, 229-239 (1995).
20. Timpl P, Spanagel R, Sillaber I et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat. Gene. 19, 162-166 (1998).
21. Takao T, Hashimoto K, Ota Z. Effect of atrial natriuretic peptide on acetylcholine-induced release of corticotropin-releasing factor from rat hypothalamus in vitro. Life Sci. 42, 1199-1203 (1988).
22. Ibanez-Santos J, Tsagarakis S, Rees LH, Besser GM, Grossman A. Atrial natriuretic peptides inhibit the release of corticotropin-releasing factor-41 from the rat hypothalamus in vitro. J. Endocrinol. 126, 223-228 (1990).
23. Antoni FA, Hunter EFM, Lowry PJ, Noble JM, Seckl JR. Atriopeptin: an endogenous corticotropin-release inhibiting hormone. Endocrinol 130, 1753-1755 (1992).
24. Vesely DL, San Miguel GI, Hassan I, Schocken DD. Atrial natriuretic hormone, vessel dilator, long-acting natriuretic hormone and kaliureitc hormone decrease the circulating concentrations of CRH, corticotropin and cortisol. J. Clin Endocrinol. Metab. 86, 4244-4249 (2001).
25. Jessop DS. Central nonglucocorticoid inhibitors of the hypothalamo-pituitary-adrenal axis. J. Endocrinol. 160, 169-180 (1999).
26. Haug C, Grunt M, Schmid S et al. Effect of corticotropin releasing factor on atrial natriuretic peptide release from the isolated perfused rat heart. Arzeimittelforschung 44, 579-582 (1994).
27. Tojo K, Sato S, Tokudome G et al. Stimulation by corticotropin-releasing factor of atrial natriuretic peptide and brain natriuretic peptide secretions from cultured neonatal rat cardiomyocytes. Biochem Biophys. Res. Commun. 225, 340-346 (1996).
28. Colao A, Pivonello R, Ferone D et al. Effect of corticotrophin-releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushing's disease. Clin. Endocrinol. 49, 77-84 (1998).
29. Lim AT, Sheward WJ, Copolov D, Windmill D, Fink G. Atrial natriuretic factor is released into hypophysial portal blood direct evidence that atrial natriuretic factor may be a neurohormone involved in hypothalamic pituitary control. J. Neuroendocrinol. 2, 15-17 (1990).
30. King MS, Baertschi AJ. Physiological concentrations of atrial natriuretic factors with intact N-terminal sequences inhibit corticotropin-releasing factor-stimulated adrenocorticotropin secretion from cultured anterior pituitary cells. Endocrinology 124, 286-292 (1989).
31. Dayanithi G, Antoni FA. Atriopeptins are potent inhibitors of ACTH secretion by rat anterior pituitary cells in vitro: involvement of the atrial natriuretic factor receptor domain of membrane-bound guanylyl cyclase. J. Endocrinol. 125, 39-44 (1990).
32. Naruse M, Obana K, Naruse K et al. Atrial natriuretic peptide inhibits cortisol secretion as well as aldosterone secretion in vitro from human adrenal tissue. J. Clin. Endocrinol. Metab. 64, 10-16 (1987).
33. Kellner M, Wiedemann K, Holsboer F. Atrial natriuretic factor inhibits the CRH-stimulated secretion of ACTH and cortisol in man. Life. 50, 1835-1842 (1992).
34. Gardner DG, Gertz BJ, Deschepper CF, Kim DY. Gene for the rat atrial natriuretic peptide is regulated by glucocorticoids in vitro. J. Clin. Invest. 89, 1275-1281 (1988).
35. Fink G, Dow RC, Casley D et al. Atrial natriuretic peptide is a physiological inhibitor of ACTH release: evidence from immunoneutralization in vivo. J. Endocrinol. 131, R9-R12 (1991).
36. Ur E, Faria M, Tsagarakis, S, Anderson JV, Besser GM, Grossmann A. Atrial natriuretic peptide in physiological doses does not inhibit the ACTH or cortisol response to corticotrophin-releasing hormone-41 in normal human subjects. J. Endocrinol. 131, 163-167 (1991).
37. Wittert GA, Espiner EA, Richards AM, Donald RA, Livesey JH, Yandle TG. Atrial natriuretic factor reduces vasopressin and angiotensin II but not the ACTH response to acute hypoglycaemic stress in normal men. Clin. Endocrinol. 38, 183-189 (1993).
38. Wiedemann K, Herzog L, Kellner M. Atrial natriuretic hormone inhibits corticotropin-releasing hormone-induced prolactin release in man. J. Psychiat. Res. 29, 51-58 (1995).
39. Kellner M, Herzog L, Holsboer F, Wiedemann K. Circadian changes in the sensitivity of the corticotropin-releasing hormone-stimulated HPA system after arginine vasopressin and atrial natriuretic hormone in human male controls. Psychoneuroendocrinology 20, 515-524 (1995).
40. Bierwolf C, Burgemeister A, Luthke K, Bom J, Fehm HL. Influence of exogenous atrial natriuretic peptide on the pituitary-adrenal response to corticotropin-releasing hormone and vasopressin in healthy men. J. Clin. Endocrinol. Metab. 83, 1151-1157 (1998).
41. Ströhle A, Kellner M, Holsboer F, Wiedemann K. Atrial natriuretic hormone decreases endocrine response to a combined dexamethasone-corticotropin-releasing hormone test. Biol. Psychiatry 43, 371-375 (1998).
42. Charles CJ, Espiner EA, Richards AM, Donald RA. Central c-type natriuretic peptide augments the hormone response to hemorrhage in conscious sheep. Peptides 16, 129-132 (1995).
43. Kellner M, Diehl I, Knaudt K, Schüle C, Jahn H, Wiedemann K. C-type natriuretic peptide exerts stimulatory effects on the corticotropin-releasing hormone-induced secretion of hormones in normal man. Eur. J. Endocrinol. 136, 388-393 (1997).
44. Hollander F, Liebowitz MR, Gorman JM, Cohen B, Fyer A, Klein DE Cortisol and sodium lactate-induced panic. Arch. Gen. Psychiatry 46, 135-140 (1989).
45. Targum SD. Cortisol response during different anxiogenic challenges in panic disorder patients. Psychoneuroendocrinology 17, 453-458 (1992).
46. Cameron OG, Lee MA, Curtis GC, McCann DS. Endocrine and physiological changes during 'spontaneous' panic attacks. Psychoneuroendocrinology 12, 321-331 (1987).
47. Liebowitz ML, Gorman JM, Fyer AJ et al. Lactate provocation of panic attacks: II: biochemical and physiological findings. Arch. Gen. Psychiatry 42, 709-719 (1985).
48. Kellner M, Herzog L, Yassouridis A, Holsboer F, Wiedemann K. Possible role of atrial natriuretic hormone in pituitary-adrenocortical unresponsiveness in lactate-induced panic. Am J. Psychiatry 152, 1365-1367 (1995). First report to investigate putative role of atrial natriuretic peptide in the hypothalamic-pituitary-adrenocortical paradox in panic.
49. Kellner M, Knaudt K, Jahn H, Holsboer F, Wiedemann K. Atrial natriuretic hormone in lactate-induced panic attacks: mode of release and endocrine and pathophysiological consequences. J. Psychiatry Res. 32, 37-48 (1998).
50. Kellner M, Wiedemann K. Nonresponse of adrenocorticotropic hormone in first-ever lactate-induced panic attacks in healthy volunteers. Arch. Gen. Psychiatry 55, 85-86 (1998).
51. Klein DF. False suffociation alarms, spontaneous panics and related conditions: an integrative hypothesis. Arch. Gen. Psyychiatry 50, 306-317 (1993).
52. Roy-Byrne PP, Uhda TW, Post RM, Gallucci W, Chrousos GP, Gold PW. The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am. J. Psychiatry 143, (896-899) 1986.
53. Holsboer F, von Bardeleben U, Buller R, Heuser I, Steiger A. Stimulation response to corticotropin-releasing hormone (CRH) in patients with depression, alcoholism and panic disorder. Horm. Metab. Res. 19, 80-88 (1987).
54. Schreiber W, Lauer CJ, Krumrey K, Holsboer F, Krieg JC. Dysregulation of the hypothalamic-pituitary-adrenocortical system in panic disorder. Neuropsychopharmacology (1997).
55. Seier FE, Kellner M, Yassouridis A, Heese R, Strian F, Wiedemann K. Autonomic reactivity and hormonal secretion in lactate-induced panic attacks. Am. J. Physiol. 272, H2630-H2638 (1997).
56. Butler GC, Senn BL, Floras JS. Influence of atrial natriuretic factor on heart rate variability in normal men. Am. J. Physiol. 267, H500-H505 (1994).
57. Harro J, Vasar E, Bradwejn J. CCK in animal and human research on anxiety. TIPS 14, 244-249 (1993).
58. Wiedemann K, Jahn H, Yassouridis A, Kellner M. Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings. Arch. Gen. Psychiatry 58, 371-377 (2001). First report on psychotropic effects of ANP in humans.
59. Kellner M, Wiedemann K. Atrial natriuretic hormone responses to clonidine in patients with panic disorder and in healthy control subjects. Eur. J. Endocrinol. 137, 84-85 (1997).
60. Poggioli R, Vergoni AV, Rasori E, Marrama D, Bertolini A. Behavioral effects of atriopeptin in rats. Neuropeptides 22, 149-154 (1992).
61. Bidzseranava A, Gueron J, Toth G, Penke B, Varga J, Teledgy G. Behavioral effects of atrial natriuretic and brain natriuretic peptides in rats. Neurorep. 3, 283-285 (1992).
62. Bhattacharya SK, Chakrabarti A, Sandler M, Glover V. Anxiolytic activity of intraventricularly administered atrial natriuretic peptide in the rat. Neuropsychopharmacology 15, 199-206 (1996).
63. Biró É, Toth G, Telegdy G. Involvement of neurotransmitters in the 'anxiolytic-like' action of atrial natriuretic peptide in rats. Neuopeptides 29, 215-220 (1995).
64. Ströhle A, Jahn H, Montkowski A et al. Central and peripheral administration of atriopeptin is anxiolytic in rats. Neuroendocrinology 65, 210-215 (1997).
65. Montkowski A, Jahn H, Ströhle A, Poettig M, Holsboer F, Wiedemann K. C-type natriuretic peptide exerts effects opposing those of atrial natriuretic peptide on anxiety-related behaviour in rats. Brain Res. 792, 358-360 (1998).
66. Samson WK, Scala KD, Huang FLS. CNP-22 stimulates, rather than inhibits, water drinking in the rat: evidence for an unique biological action of the C-type natriuretic peptides. Brain Res. 568, 285-288 (1992).
67. Trachte GJ, Kanwal S, Elmquist BJ, Ziegler RJ. C-type natriuretic peptide neuromodulates via 'clearance' receptors. Am. J. Physiol. 268, C978-C984 (1995).
68. Jahn H, Montkowski A, Knaudt K et al. α-helical-corticotropin-releasing hormone reverses anxiogenic effects of C-type natriuretic peptide in rats. Brain Res. 893, 21-28 (2001).
69. Ströhle A, Kellner M, Holsboer F, Wiedemann K. Anxiolytic activity of atrial natriuretic peptide (ANP) in patients with panic disorder. Am. J. Psyhiatry 158, 1514-1516 (2001).
70. Biró É, Sarnyai Z, Penke B, Szabó B, Telegdy G. Role of endogenous corticotropin-releasing factor in mediation of neuroendocrine and behavioral responses to cholecystokinin octapeptide sulfate ester in rats. Neuroendocrinology 57, 340-345 (1995).
71. Kellner M, Yassouridis A, Hua Y, Wendrich M, Jahn H, Wiedemann K. Intravenous C-type natriuretic peptide augments behavioral and endocrine effects of choleystokinin tetrapeptide in healthy man. J. Psych. Res. 36, 1-6 (2002). First report on psychotropic effects of CNP in man.